Pasithea Therapeutics (KTTA) confirmed that an independent special committee of its Board of Directors thoroughly reviewed and rejected an unsolicited, non-binding proposal from Lucy Scientific Discovery (LSDI) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock. After a comprehensive review, conducted in consultation with its independent financial and legal advisors, the Special Committee determined that the Lucy proposal does not reflect Pasithea’s strategic value and prospects for continued growth and, as such, is not in the best interests of the Company or its stockholders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KTTA:
- Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
- Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
- Pasithea Therapeutics confirms creation of independent special committee
- Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
- Lucy Scientific Discovery reiterates proposal to acquire Pasithea Therapeutics
